Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)
Launched by MAYO CLINIC · Aug 30, 2011
Trial Information
Current as of August 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Study question: Do mutations within certain genes cause or confer susceptibility to spontaneous coronary artery dissection (SCAD)?
Specific aims:
1. Create a genomic DNA and plasma biobank for individuals diagnosed with SCAD.
2. Identify inherited and de novo/new mutations that underlie SCAD.
3. Identify common genetic variants that confer risk for SCAD.
Long term objective:Discover molecular and cellular mechanisms of SCAD and develop biomarkers to enable prediction and prevention.
The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause tears ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women able to give informed consent and complete a 2 page questionnaire
- • Diagnosis of one or more episodes of spontaneous coronary artery dissection (SCAD)
- • Biological parent of individual with SCAD
- • Relative with fibromuscular dysplasia, arterial aneurysm, or arterial dissection
- Exclusion Criteria:
- • Lack of confirmation of SCAD diagnosis
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Sharonne N. Hayes, M.D.
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials